MG
ALXN

Michael Gelband’s Alexion Pharmaceuticals ALXN Stock Holding History

Michael Gelband’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,829
Closed -$1.24M – 2553
2020
Q3 		$1.24M Sell
10,829
-20,568
-66% -$2.22M 0.02% 601
2020
Q2 		$3.52M Buy
31,397
+9,772
+45% +$1.04M 0.09% 244
2020
Q1 		$1.94M Buy
+21,625
New +$2.12M 0.11% 187
2019
Q4 		– Sell
-3,000
Closed -$294K – 2022
2019
Q3 		$294K Sell
3,000
-31,259
-91% -$3.52M 0.01% 889
2019
Q2 		$4.49M Buy
+34,259
New +$4.42M 0.18% 78

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Michael Gelband's ALXN Position: Q4 2020 in Review

Michael Gelband sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 10,829 shares — an estimated $1.24M sold.

Michael Gelband first reported a position in ALXN in Q2 2019 and held it in 5 quarters. The position peaked at $4.49M in Q2 2019. 825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Michael Gelband reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Michael Gelband sold 10,829 Alexion Pharmaceuticals shares in Q4 2020, an estimated $1.24M.
  • Michael Gelband first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Michael Gelband's Alexion Pharmaceuticals position peaked at $4.49M in Q2 2019.
  • 825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on ExodusPoint Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.